HER2 was downregulated but still detectable in JIMT-1 breast cancer xenografts (immunohistochemistry score 1+) that had progressed on both T-DM1 and T-DXd, suggesting that these cross-resistant tumors remain potentially targetable with anti-HER2 therapies. This evidence concerns the gene ERBB2 and breast cancer.